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INTRODUCTION
The microorganism’s ability to infect and colonise im-
planted biomaterial or some other medical device still re-
mains as a risk factor in the development of nosocomial in-
fections. There have been many recent studies that examine
the risk of microbial contamination of biomaterials (Hetrick
et al., 2006). Infections continue to spread in all fields of
medicine related to the implantation of biomaterials. One of
the major obstacles against wider use of biomaterial im-
plants is the capacity of bacteria to attach to biomaterial sur-
faces, which can cause infections associated with biomateri-
als (Yuehuei et al., 1998).
Major pathogens of implant-related infections are staphylo-
cocci (Staphylococcus aureus and coagulase-negative staph-
ylococci, such as S. epidermidis), which are aetiology
agents in 25% of all implant infections (McCann et al.,
2008; Hodgson et al., 2014).
S. epidermidis has become the leading pathogen of
nosocomial infections. The infection usually develops after
joint replacement surgery, central venous catheter implanta-
tions and artificial heart valve operations. S. epidermidis has
a Gram-positive cell wall structure. It is a non-motile and
non-spore forming bacteria, which can be easily recognized
by microscopic examination, as they form spherical cell
clusters resembling bunches of grapes (Kiedrowski et al.,
2011). Coagulase-negative Staphylococcus are among the
most frequently isolated bacteria in clinical microbiology
laboratories. Bacteria are part of the normal human skin and
mucous membrane microflora, and therefore one of the
most important tasks of daily diagnostic work is to distin-
guish clinically significant coagulase-negative Staphylococ-
cus infection from the normal microflora (von Eiff et al.,
2002). S. epidermidis belongs to the normal microflora of
the skin and mucous membrane. It has the unique and spe-
cific property of biofilm formation on implanted biomateri-
als. The ability of S. epidermidis to colonise and build
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Infections continue to spread in all fields of medicine, and especially in the field of implant
biomaterial surgery, and not only during the surgery, but also after surgery. Reducing the adhe-
sion of bacteria could decrease the possibility of biomaterial-associated infections. Bacterial ad-
hesion could be reduced by local antibiotic release from the biomaterial. In this in vitro study,
hydroxyapatite biomaterials with antibiotics and biodegradable polymers were tested for their abil-
ity to reduce bacteria adhesion and biofilm development. This study examined the antibacterial
efficiency of hydroxyapatite biomaterials with antibiotics and biodegradable polymers against
Staphylococcus epidermidis and Pseudomonas aeruginosa. The study found that hydroxyapatite
biomaterials with antibiotics and biodegradable polymers show longer antibacterial properties
than hydroxyapatite biomaterials with antibiotics against both bacterial cultures. Therefore, the re-
sults of this study demonstrated that biomaterials that are coated with biodegradable polymers re-
lease antibiotics from biomaterial samples for a longer period of time and may be useful for
reducing bacterial adhesion on orthopedic implants.
Key words: S. epidermidis, P. aeruginosa, antimicrobial agents, composite materials, biodegrad-
able polymers.
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biofilms on biomaterial implants depends on composition
and surface properties of the biomaterial, as well as the abil-
ity to produce micro-adhesins (O’Gara et al., 2001;
Christner et al., 2010).
Many studies have shown that the S. epidermidis biofilm
formation process consists of two phases, defined by bio-
chemical and molecular-cellular levels. In the first phase,
the biochemical level, bacterial extracellular polysaccharide
adhesins play a primary role in initial bacterial adhesion and
mutual adhesion of bacteria (Agarwal et al., 2010).
Gram-negative pathogens such as Pseudomonas aeruginosa
are the second most important aetiological agents in im-
plant-related infections (Peel et al., 2012). They can cause
life-threatening nosocomial infections, particularly for
immunocompromised patients and burn patients (Pruitt et
al., 1998; Cunha, 2001). The bacterium is widely present in
the external environment — soil, water, and in the hospital
environment. High antibacterial resistance and the ability to
produce a biofilm on artificial surfaces makes bacterial in-
fections difficult to treat and deadly to the patient (Hoiby et
al., 2001; Drenkard, 2003). P. aeruginosa biofilms are
formed in five phases, starting with free plankton cell adhe-
sion to the surface, followed by microcolony formation, and
finally the dispersion. Paeruginosa biofilm is composed of
a mixture of polysaccharides, nucleic acids and proteins
(Harmsen et al., 2007).
The role of other microorganisms such as enterococci,
streptococci, and fungi in implant related infections has also
been proven. About 40% of cases of infection by Propioni-
bacterium acnes (member of the skin deep microflora) are
associated with shoulder joint prosthesis infections (Zeller
et al., 2007; Sampedro et al., 2009).
To avoid the risk of postoperative infections and in order to
prevent bacterial biofilm development on biomaterials, the
optimal solution is the use of antibiotics. Biomaterials with
local antibiotic release are being used increasingly nowa-
days, because they have significant advantages over sys-
temic use of antibiotics (Grainger et al., 2013). Systemic
antibiotic therapy has several disadvantages: low bioavail-
ability, poor penetration in bacterial infection areas and an-
tibiotic side effects, and ability of bacteria to develop resis-
tance to antibiotics (Pritchard et al., 2013).
Polymer particles, including nanoparticles and microparti-
cles created from natural and synthetic polymers have dem-
onstrated several advantages. Polymers can be connected to
antibiotics and the biomaterial surface creating high anti-
bacterial stability in vitro and in vivo, good biological com-
patibility and multi-functionality. Good potential efficiency
is predicted for biomaterials with surfaces with antibiotics
immobilized with polymer, which provide steady, sustained
release of antibiotics from the implant into tissues. This re-
sults in good efficiency in controlling biofilm-producing
bacteria. Among the various biodegradable polymers,
poly(L-lactic acid) (PLLA) and polycaprolactone (PCL) are
widely used in various industries, as they can be derived
from renewable resources. PLLA is widely used in surgical
implants, biodegradable floss and tissue culture (Armentano
et al., 2010). The aim of this study was to determine the an-
tibacterial efficiency of hydroxyapatite biomaterials with
biodegradable polymers and antibiotics.
MATERIALS AND METHODS
Hydroxyapatite composite material HAp/PLLA+cipro,
HAp/PLLA+genta. Hydroxyapatite (HAp) powder was
prepared by wet chemical precipitation synthesis from cal-
cium oxide (CaO, Fluka, 97 %) and ortophosphoric acid
(Sigma-Aldrich,  85%) solution (Sokolova et al., 2014).
The obtained as-synthesized powders were uniaxially
pressed into pellets (d = 10, H = 3 mm). All samples were
sintered at 1100 °C for 1 hour.
To load drugs in the HAp scaffolds, gentamicin (genta) or
ciprofloxacin (cipro) was dissolved in deionised water at
concentrations of 40 mg/ml of genta and 100 mg/10 ml of
cipro. The scaffolds were impregnated with the aqueous
drug solution at room temperature, followed by drying at 37
°C. Part of the prepared samples were coated with PLLA.
We prepared solutions of 10 wt% PLLA (Nature Works
LLC, Mw = 110 kDa) in dichlormethane (DCM) (Sigma-
Aldrich, UK) in order to coat the prepared HAp scaffolds
with polymers. PLLA was dissolved in DCM by stirring for
2 h at room temperature. Polymer solution was infiltrated in
HAp bioceramic scaffolds using the vacuum impregnation
technique at 500 mbar pressure for 15 min. The coated scaf-
folds were dried at room temperature for 24 h.
The open (P0) porosity and total (Pt) porosity of scaffolds
was determined by the Archimedes method based on the
principle that buoyant force is equal to the weight of the
fluid displaced (Locs et al., 2013).
Observations of the microstructure of coated scaffold cross-
sections by scanning electron microscope (SEM) showed
that HAp/PLLA scaffolds coated with 10 wt% of PLLA ex-
hibited a porous microstructure with pore size estimated to
be in the range of 200 nm to 500 nm (Fig. 1.).
Calcium deficient composite materials CDHAp/PCL+
cipro, CDHAp/PCL+genta, CDHAp/PLLA+cipro
CDHAp/ PLLA+genta. Calcium deficient hydroxyapatite
(CDHAp) powders were synthesised via wet precipitation
reaction using the following reactants: calcium oxide (CaO,
Fluka, from marble, 97%) and orthophosphoric acid
(H3PO4, Sigma-Aldrich, 85%) and deionised water. Mul-
tiple factors were evaluated for effect on product phase
composition: e.g., suspension temperature, pH level, acid
addition rate and mixing (Sokolova et al., 2014).
PCL, PLLA, and CDHAp composites with a range of bio-
polymer content (20 wt% and 30 wt%) were manufactured
using modified novel liquid/solid suspension technology.
Genta was dissolved in deionised water to a concentration
of 40 mg/ml. Cipro was dissolved in deionised water to a
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concentration of 100 mg/10 ml. Predetermined amounts of
the solution were mixed with different CDHAp/PCL and
CDHAp/PLLA powders to yield 6 wt% genta or cipro in fi-
nal composition. The obtained powder blends were dried at
room temperature for 24 h. The obtained composite material
was uniaxially and isostatically pressed into pellets (d =
12.5 mm, H = 2.2 mm).
The porosity of CDHAp/PCL and CDHAp/PLLA beads
was determined by the geometrical method. Very low total
porosities of 13–15 % were obtained for CDHAp/PCL and
CDHAp/PLLA composites. CDHAp+cipro, CDHAp+genta,
CDHAp/PLLA samples were prepared using the method de-
scribed above.
Antibacterial efficiency in Trypticase soy broth (TSB)
buffer. The HAp biomaterial disks were firstly eluted in
rabbit blood plasma at 37 °C in 5% CO2 atmosphere and
100% relative humidity for 2 h. Biomaterials of all groups
were incubated at 37 °C for 24 h in 2 ml TSB (Oxoid, UK)
with 1 ml bacteria suspension. The suspension had optical
density of 0.5 according to the McFarland standard. 2 ml
TSB bacteria suspension alone with optical density of 0.5
(according to the McFarland standard), was used as the con-
trol. After 24 h incubation, to test the antibacterial effi-
ciency of the studied biomaterials, 0.1 ml suspension was
cultured on trypticase soy agar (TSA) (Oxoid, UK). In addi-
tion, after the incubation, the biomaterials of all studied
groups were transferred to new rabbit blood plasma at 37 °C
with 5% CO2 atmosphere and 100% relative humidity for
2 h, and then to a new TSB and bacterial culture suspension
for 24 hours. This was every 24 hours for two days. No an-
tibacterial effect was observed in the tested biomaterial
groups, as number of TSA colonies was equivalent to that
of the control.
Bacterial cultures. Antibacterial efficiency of all biomate-
rials was tested using S. epidermidis (ATCC 12228) and P.
aeruginosa (ATCC 27853) bacteria reference cultures.
Statistical analysis. The Mann-Whitney test was used to
assess statistically significant differences between antibacte-
rial effect of different biomaterial samples. Statistically sig-
nificant was assumed if p was less than or equal to 0.05.
Statistical analyses were performed with software SPSS
22.0.
RESULTS
Antibacterial efficiency tests showed that the mean when
time when biomaterial samples with biodegradable polymer
and antibiotics had antibacterial effect against S. epiderm-
idis and P. aeruginosa was significantly longer (p < 0.01)
than for biomaterial samples with antibiotics against S.
epidermidis and P. aeruginosa and without biodegradable
polymer (Fig. 2). No antibacterial properties of HAp/PLLA,
CDHAp/PLLA, and CDHAp/PCL samples were observed.
Samples with biodegradable PCL show significantly longer
(p < 0.01) antibacterial effect than samples with biodegrad-
able PLLA for both antibiotics used in the study.
In the first six days of the study (144 h) the growth of S.
epidermidis was almost completely inhibited in CDHAp/
PLLA+cipro and HAp/PLLA+cipro samples. In the follow-
ing five days, CDHAp/PLLA+cipro and Hap/PLLA+cipro
samples released antibiotics, but did not completely inhibit
the growth of S. epidermidis, and the relative bacterial inhi-
bition gradually decreased. In the first hours of the study,
the growth of S. epidermidis was completely inhibited in
CDHAp+cipro and HAp+cipro samples, however subse-
quently this effect rapidly decreased (Fig. 3).
The time period of antibacterial effect of HAp/PLLA+genta
and CDHAp/PLLA+genta on S. epidermidis was longer
(Fig. 4) than that of HAp+genta and CDHAp+genta.
Inhibition of S. epidermidis growth by CDHAp/PCL+cipro
samples was more effective than for CDHAp/PLLA+cipro,
as almost complete inhibition continued for an additional
two days (p < 0.01); almost complete inhibition occurred
for eight days (192 hours), with subsequent decrease over
five days. The S. epidermidis growth inhibition effect of
CDHAp/PCL+genta samples was very similar to that of
CDHAp/PCL+cipro samples, but its antibacterial efficacy
extended for one day longer. CDHAp+genta and CDHAp+
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Fig. 1. SEM micrographs of cross-sec-
tion of HAp/PLLA coated scaffold A –
pore diameter in the range of 200 nm to
500 nm, B – PLLA coating (2–5 µm
thick).
cipro samples rapidly lose their ability to inhibit the growth
of S. epidermidis. (Fig. 5).
Almost complete P. aeruginosa growth inhibition by
CDHAp/PLLA+cipro samples was observed for four days
(96 h). In the subsequent four days, P. aeruginosa growth
inhibition was gradually reduced, and the time period of an-
tibacterial effect was nine days (187.2 hours). The
antibacterial time period of effect of CDHAp+cipro samples
was three days; complete P. aeruginosa growth inhibition
was observed on the first day, and in the next two days there
was a rapid decline in the inhibitory effect (Fig. 6).
CDHAp/ PCL+cipro samples had a similar effect to that of
CDHAp/ PLLA+cipro samples; CDHAp/PCL+cipro sam-
ples show significantly longer (p < 0.01) antibacterial effect
(280.8 hours) and complete inhibition of P. aeruginosa
growth occurred for and additional three days. (Fig. 7).
There is no significant difference (p < 0.01) between anti-
bacterial properties of Hap/PLLA+genta and CDHAp/
PLLA+genta samples against P. aeruginosa (Fig. 8).
DISCUSSION
Implant-related infections are among the most common
complications associated with any biomaterial infection, re-
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Fig. 2. Antibacterial efficiency in vitro testing of CDHAp/PCL+cipro
(n = 5), CDHAp+cipro (n = 5), CDHAp/PLLA+cipro (n = 5),
CDhap/PCL (n = 5), CDHAp/PCL+genta (n = 5), CDHAp/PLLA (n =
5), CDHAp+genta (n = 5), CDHAp/PLLA+genta (n = 5),
Hap/PLLA+cipro (n = 5), Hap+cipro (n = 5), Hap/PLLA (n = 5),
Hap+genta (n = 5), Hap/PLLA+genta (n = 5) against S. epidermidis
and P. aeruginosa. Data presented as mean antibacterial time ± SD.
Fig. 3. Dynamics of S. epidermidis growth inhibition. Data presented as
mean relative (%) bacterial growth inhibition.
Fig. 4. Dynamics of S. epidermidis growth inhibition. Data presented as
mean relative (%) bacterial growth inhibition.
Fig. 5. Dynamics of S. epidermidis growth inhibition. Data presented as
mean relative (%) bacterial growth inhibition.
gardless of form or function. These infections usually in-
volve bacterial colonisation and later biofilm formation on
biomaterials (Reinis et al., 2010). These infections are not
susceptible to antimicrobial agents, and are protected by the
immune system of the host. In addition, it becomes increas-
ingly clear that the infection in the surrounding tissue plays
an important role in implant related infections, and compo-
sition and design implanted biomaterials can have an effect
on the infection (Busscher et al., 2012).
Two main routes are well known when implanted objects
become a target of bacteria: 1) direct implant contamination
with bacteria during surgical rocedures. Bacteria colonises
the surface of biomaterials during surgery. The patient’s
skin or mucosal microflora, air microflora, or microflora of
medical staff could be the source of bacterial contamina-
tion; 2) bacteria reaching the implant with haematogenous
dissemination, and invoking a late implant infection. The
bacterial contamination source is likely skin and mucous
membrane microflora (Zimmerli et al., 2004).
When bacteria are bound to implanted biomaterials, pheno-
typic changes occur and bacteria become associated with
the surface structure. The attached bacteria begin to secrete
an extracellular matrix (glycocalyx) on the implanted bio-
material surface. Glycocalyx encompasses bacterial colo-
nies on the implant, forming a biofilm (Costerton et al.,
1999).
Antibiotics should be used to prevent biofilm formation on
an implanted biomaterial surface. A local antibiotic therapy
(biomaterials with antibiotics) should be used in order to
avoid systemic complications and other side effects of anti-
biotics (Li et al., 2011; Ruckh et al., 2012).
Systemic antibiotic therapy has several disadvantages, such
as low bioavailability, poor penetration of antibiotics in
bacterial infections in site, side effects, as well as the ability
of bacteria to develop resistance to antibiotics (Xu et al.,
2008; Lepretre et al., 2009).
Biomaterials that are impregnated with antibiotics for local
antibiotic release can be used to avoid complications from
systemic antibiotic usage. A large number of studies have
aimed to develop new and effective local antibiotic release
systems from biomaterials (Guo et al., 2013). In these stud-
ies, a wide variety of biomaterials impregnated with differ-
ent antibiotics have been investigated. Most often these an-
tibiotics are commonly used, incluiding in hospitals to treat
and prevent implants from possible infections. Studies on
biomaterials that are covered with a biodegradable polymer
and antibiotics have demonstrated longer periods of antibac-
terial effect and protection of the implant from infection. In
the present study, we examined two leading causative
agents of implant-related infections, which form biofilms
(Xiong et al., 2012; Jaiswal et al., 2015).
The results showed that biomaterial samples covered with
biodegradable PLA polymers have longer periods of anti-
bacterial effect and thus they are more effective in protect-
ing an implant from infections, compared to biomaterial
samples without a PLLA polymer. A large number of stud-
ies have reported similar results, showing that biomaterials
with biodegradable polymers maintain antibacterial proper-
ties for longer periods of time (Belcarz et al., 2009).
Another factor that can affect the period of antibacterial ac-
tivity is the porosity of biomaterial samples. In our study,
samples with higher porosity levels showed more sustained
antibacterial properties, and thus needs to be examined in
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Fig. 6. Dynamics of P. aeruginosa growth inhibition. Data presented as
mean relative (%) bacterial growth inhibition.
Fig. 7. Dynamics of P. aeruginosa growth inhibition. Data presented as
mean relative (%) bacterial growth inhibition.
Fig. 8. Dynamics of P. aeruginosa growth inhibition. Data presented as
mean relative (%) bacterial growth inhibition.
other studies on implant related infections (Chai et al.,
2007; Meurice et al., 2012).
CONCLUSION
HAp samples with antibiotics and biodegradable polymers
ensure slow secretion of antibiotic substances. The polymer
(PLLA or PCL) is degraded slowly and it also ensures a
slow secretion of antibiotic substances. However, in situa-
tions when HAp samples are saturated with antibiotic sub-
stances and they are not covered by biodegradable polymers
(PLLA or PCL), antibiotics secrete rapidly, thus providing
protection from infection for a shorter period of time and in-
creasing risk of developing implant-related infections.
The authors declare that there is no conflict of interests re-
garding the publication of this paper.
REFERENCES
Agarwal, A., Singh, K. P., Jain, A. (2010). Medical significance and manage-
ment of staphylococcal biofilm. FEMS (Federation of European Microbi-
ological Societies) Immunol. Med. Microbiol. 58, 147–160.
Armentano, I., Dottori, M., Fortunati, E., Mattioli, S., Kenny, J. M. (2010).
Biodegradable polymer matrix nanocompositesfor tissue engineering: A
review. Polymer Degrad. Stability, 95 (11), 2126–2146.
Belcarz, A., Ginalska, G., Zalewska, J., Rzeski, W., Slósarczyk, A.,
Kowalczuk, D., Godlewski, P., Niedêwiadek, J. (2009). Covalent coating
of hydroxyapatite by keratin stabilizes gentamicin release. J. Biomed. Ma-
ter. Res. B. Appl. Biomater., 89 (1), 102–113.
Busscher, H. J., van der Mei, H. C., Subbiahdoss, G., Jutte, P. C., van den
Dungen, J. J. A. M., Zaat, S. A. J., Schultz, M. J., Grainger, D. W. (2012).
Biomaterial-associated infection: Locating the finish line in the race for the
surface. Sci. Transl. Med., 4 (153), 153rv10.
Chai, F., Hornez, J. C., Blanchemain, N., Neut, C., Descamps, M.,
Hildebrand, H. F. (2007). Antibacterial activation of hydroxyapatite (HA)
with controlled porosity by different antibiotics. Biomol. Eng., 24 (5),
510–514.
Christner, M., Franke, G. C., Schommer, N. N., Wendt, U., Wegert, K.,
Pehle, P., Kroll, G., Schulze, C., Buck, F., Mack, D., Aepfelbacher, M.,
Rohde, H. (2010). The giantextracellularmatrix-binding protein of Staphy-
lococcus epidermidis mediates biofilm accumulation and attachment to
fibronectin. Mol. Microbiol., 75, 187–207.
Costerton, J. W., Stewart, P. S., Greenberg, E. P. (1999). Bacterial biofilms:
A common cause of persistent infections. Science, 284 (5418), 1318–1322.
Cunha, B. A. (2001). Nosocomial pneumonia. Diagnostic and therapeutic
considerations. Med. Clin. North Amer., 85 (1), 79–114.
Drenkard, E. (2003). Antimicrobial resistance of Pseudomonas aeruginosa
biofilms. Microbes Inf., 5, (13), 1213–1219.
Grainger, D. W., van der Mei, H. C., Jutte, P. C., van den Dungen, J. J.,
Schultz, M. J., van der Laan, B. F., Zaat, S. A., Busscher, H. J. (2013). Criti-
cal factors in the translation of improved antimicrobial strategies for medi-
cal implants and devices. Biomaterials, 34 (37), 9237–9343.
Guo, Y. J., Long, T., Chen, W., Ning, C., Zhu, Z. A., Guo, Y. P. (2013). Bac-
tericidal property and biocompatibility of gentamicin-loaded mesoporous
carbonated hydroxyapatite microspheres. Mater. Sci. Eng. C. Mater. Biol.
Appl., 33 (7), 3583–3591.
Harmsen, M., Yang, L., Pamp, S. J., Tolker-Nielsen, T. (2010). An update on
Pseudomonas aeruginosa bioflm formation, tolerance, and dispersal.
FEMS Immunol Med. Microbiol., 59, 253–268.
Hetrick, E. M., Schoenfisch, M. H. (2006). Reducing implant-related infec-
tions: Active release strategies. Chem. Soc. Rev., 35 (9), 780–789.
Hodgson, S. D., Greco-Stewart, V., Jimenez, C. S., Sifri, C. D., Brassinga, A.
K. C., Ramirez-Arcos, S. (2014). Enhanced pathogenicity of biofilm-nega-
tive Staphylococcus epidermidis isolated from platelet preparations. Trans-
fusion, 54 (2), 461–470.
Hoiby, N., Krogh Johansen, H., Moser, C., Song, Z., Ciofu, O., Kharazmi, A.
(2001). Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode
of growth. Microbes Inf., 3 (1), 23–35.
Jaiswal, S., Bhattacharya, K., McHale, P., Duffy, B. (2015). Dual effects of
-cyclodextrin-stabilised silver nanoparticles: Enhanced biofilm inhibition
and reduced cytotoxicity. J. Mater. Sci. Mater. Med., 26 (1), 5367
Jr. Pruitt, B. A., McManus, A. T., Kim, S. H., Goodwin, C. W. (1998). Burn
wound infections: Current status. World J. Surg., 22, 135–145.
Kiedrowski, R. M., Horswill, A. R. (2011). New approaches for treating
staphylococcal biofilm infections. Ann. NY Acad. Sci., 1241, 104–121.
Lepretre, S., Chai, F., Hornez, J. C., Vermet, G., Neut, C., Descamps, M.,
Hildebrand, H. F., Martel, B. (2009). Prolonged local antibiotics delivery
from hydroxyapatite functionalised with cyclodextrin polymers.
Biomaterials, 30, 6086–6093
Li, Z., Kong, W., Li, X., Xu, C., He, Y., Gao, J., Ma, Z., Wang, X., Zhang, Y.,
Xing, F., Li, M., Liu, Y.. Antibiotic-containing biodegradable bead clusters
with porous PLGA coating as controllable drug-releasing bone fillers. J.
Biomater. Sci. Polym. Ed., 22 (13), 1713–1731
Locs, J., Zalite, V., Berzina-Cimdina, L., Sokolova, M. (2013). Ammonium
hydrogen carbonate provided viscous slurry foaming — a novel technol-
ogy for the preparation of porous ceramics. J. Eur. Ceram. Soc., 33,
3437–3443.
McCann, M. T., Gilmore, B. F., Gorman, S. P. (2008). Staphylococcus
epidermidis device-related infections: Pathogenesis and clinical manage-
ment. J. Pharm. Pharmacol., 60, 1551–1571.
Meurice, E., Leriche, A., Hornez, J. C., Bouchart, F., Rguiti, E., Boilet, L.,
Descampsa, M., Cambier, F. (2012). Functionalisation of porous
hydroxyapatite for bone substitutes. J. Eur. Ceram. Soc., 32, 2673–2678.
O'Gara, J. P, Humphreys, H. (2001). Staphylococcus epidermidis biofilms:
Importance and implications. J. Med. Microbiol., 50 (7), 582–587.
Peel, T. N., Cheng, A. C., Buising, K. L., Choong, P. F. (2012). The microbi-
ological aetiology, epidemiology and clinical profile of prosthetic joint in-
fections: Are current antibiotic prophylaxis guidelines effective?
Antimicrob. Agents Chemother., 56, 2386–2391.
Pritchard, E. M., Valentin, T., Panilaitis, B., Omenetto, F., Kaplan, D. L.
(2013). Antibiotic-releasing silk biomaterials for infection prevention and
treatment. Adv. Funct. Mater., 23 (7), 854–861.
Reinis, A., Pilmane, M., Stunda, A., Vetra, J., Kroica, J., Rostoka, D., Salms,
G., Vostroilovs, A., Dons, A., Berzina-Cimdina, L. (2010). An in vitro and
in vivo study on the intensity of adhesion and colonization by Staphylococ-
cus epidermidis and Pseudomonas aeruginosa on originally synthesized
biomaterials with different chemical composition and modified surfaces
and their effect on expression of TNF-, -defensin 2 and IL-10 in tissues.
Medicina, 47 (10), 560–565.
Ruckh, T. T., Oldinski, R. A., Carroll, D. A., Mikhova, K., Bryers, J. D.,
Popat., K. C. (2012). Antimicrobial effects of nanofiber poly(caprolactone)
tissue scaffolds releasing rifampicin. J. Mater. Sci. Mater. Med., 23 (6),
1411–1420.
Sampedro, M. F., Piper, K. E., McDowell, A., Patrick, S., Mandrekar, J. N.,
Rouse, M. S., Steckelberg, J. M., Patel, R. (2009). Species of
Propionibacterium and Propionibacterium acnes phylotypes associated
with orthopedic implants. Diagn. Microbiol. Infect. Dis., 64 (2), 138–145
Sokolova, M., Putniòð, A., Kreicbergs, I., Loès, J. (2014). Scale-up of wet
precipitation calcium phosphate synthesis. Key Eng. Mater., 604, 216–219.
von Eiff, C., Peters G., Heilmann, C. (2002). Pathogenesis of infections due
to coagulase- negative staphylococci. Lancet Inf. Dis., 2 (11), 677–685.
225Proc. Latvian Acad. Sci., Section B, Vol. 70 (2016), No. 4.
Xiong, M. H., Bao, Y., Yang, X. Z., Zhu, Y. H., Wang, J. (2012). Delivery of
antibiotics with polymeric particles. Adv. Drug Delivery Rev., 78 (30),
63–76.
Xu, Q., Czernuszka, J. T. (2008). Controlled release of amoxicillin from
hydroxyapatite-coated poly (lactic-co-glycolic acid) microspheres. J. Con-
trol Release, 128 (2), 146–153
Yuehuei, H. A., Friedman, R. J. (1998). Concise review of mechanisms of
bacterial adhesion to biomaterial surfaces. Appl. Biomater., 43, 338–348.
Zeller, V., Ghorbani, A., Strady, C., Leonard, P., Mamoudy, P., Desplaces,
N. (2007). Propionibacterium acnes: An agent of prosthetic joint infection
and colonization. J. Infect., 55, 119–124.
Zimmerli, W., Trampuz, A., Ochsner, P. E. (2004). Prosthetic-joint infec-
tions. New Engl. J. Med., 351 (16), 1645–1654.
226 Proc. Latvian Acad. Sci., Section B, Vol. 70 (2016), No. 4.
BIONOÂRDÂMU POLIMÇRU SATUROÐU UN AR ANTIBIOTISKAJÂM VIELÂM PIESÛCINÂTU BIOMATERIÂLU
ANTIBAKTERIÂLÂS EFEKTIVITÂTES NOTEIKÐANA
Infekcijas slimîbas joprojâm ir aktuâla problçma medicînâ, t.sk. jomâs, kas saistîtas ar biomateriâlu implantâciju. Operâcijas laikâ un arî
pçcoperâcijas periodâ normâlâs floras baktçrijas limfogçnâs vai hematogçnâs diseminâcijas rezultâtâ var sasniegt implantçto objektu, to
kolonizçt un izsaukt infekciju. Biomateriâlu bakteriâlâ kolonizâcija sâkas ar adhçziju jeb baktçriju piesaisti pie to virsmas, lîdz ar to,
nomâcot ðo spçju, var samazinât biomateriâlu saistîto infekciju attîstîbas iespçju. Baktçriju adhçziju pie biomateriâliem var samazinât,
izmantojot lokâlu antibiotisko vielu izdales sistçmas. Ðajâ in vitro pçtîjumâ tiek izmantoti oriìinâli sintezçti biomateriâli ar bionoârdoðiem
polimçriem un antibiotiskajâm vielâm, lai samazinâtu baktçriju adhçziju un bakteriâlo biofilmu veidoðanos uz biomateriâliem. Ðo
biomateriâlu antibakteriâlâ efektivitâte tika pçtîta pret bieþâkajiem pçcoperâciju infekciju ierosinâtâjiem un biofilmu veidotâjiem – Staphy-
lococcus epidermidis un Pseudomonas aeruginosa. Pçtîjuma rezultâti parâda, ka biomateriâli ar antibiotiskajâm vielâm un bionoârdoðajiem
polimçriem uzrâda ilgâkas antibakteriâlâs îpaðîbas nekâ biomateriâli ar antibiotiskajâm vielâm bez bionoârdoðâ polimçra pret abâm
baktçriju kultûrâm. Tâdçjâdi biomateriâli ar antibiotiskajâm vielâm un bionoârdoðu polimçru ir pasargâti no baktçriju adhçzijas un sekojoðu
biofilmu veidoðanâs ilgâkâ laika periodâ.
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